HER2 Support Group Forums - View Single Post - Ariad Begins Clinical Trial of oral deforolimus, mTOR inhibitor

Rich66 · 06-01-2009, 03:35 PM

Ariad Begins Clinical Trial of Breast Cancer Drug

Luke Timmerman 7/30/08

Ariad Pharmaceuticals (NASDAQ: ARIA), the Cambridge, MA-based developer of cancer drugs, said today it has started a mid-stage clinical trial of a breast cancer treatment designed to help patients who resist Genentech’s Herceptin. The drug, an oral pill called deforolimus, is designed to block the mTOR protein, which acts like a “master switch” for cancer cells. Ariad will now receive a $15 million milestone payment from its partner, drug giant Merck (NYSE: MRK) for starting the study. The trial, of 33 patients, should wrap up in the second half of 2009.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com or call 206-624-2374.
Comments | Permalink |

Share |

E-mail

06-01-2009, 03:35 PM	#1
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	Ariad Begins Clinical Trial of oral deforolimus, mTOR inhibitor Ariad Begins Clinical Trial of Breast Cancer Drug Luke Timmerman 7/30/08 Ariad Pharmaceuticals (NASDAQ: ARIA), the Cambridge, MA-based developer of cancer drugs, said today it has started a mid-stage clinical trial of a breast cancer treatment designed to help patients who resist Genentech’s Herceptin. The drug, an oral pill called deforolimus, is designed to block the mTOR protein, which acts like a “master switch” for cancer cells. Ariad will now receive a $15 million milestone payment from its partner, drug giant Merck (NYSE: MRK) for starting the study. The trial, of 33 patients, should wrap up in the second half of 2009. Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com or call 206-624-2374. Comments \| Permalink \| Share \| E-mail